Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Breast Neoplasms 300Carcinoma, Non-Small-Cell Lung 262Neoplasms 242Prostatic Neoplasms 204Colorectal Neoplasms 187Lung Neoplasms 145Multiple Myeloma 141Neoplasm Metastasis 126Ovarian Neoplasms 123Leukemia, Myeloid, Acute 115Pancreatic Neoplasms 109Melanoma 96Squamous Cell Carcinoma of Head and Neck 93Recurrence 80Endometrial Neoplasms 78Carcinoma, Renal Cell 76Lymphoma, Non-Hodgkin 74Lymphoma 70Stomach Neoplasms 69Precursor Cell Lymphoblastic Leukemia-Lymphoma 69Carcinoma, Hepatocellular 67Glioblastoma 66Brain Neoplasms 64Sarcoma 62Glioma 62Uterine Cervical Neoplasms 59Head and Neck Neoplasms 59Triple Negative Breast Neoplasms 57Leukemia, Lymphocytic, Chronic, B-Cell 54Urinary Bladder Neoplasms 51

Interventions

trametinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Differentiated Thyroid Cancer (DTC) × 30 days × Clear all
NCT04940052 2026-06-04

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Novartis

Phase 3 Active not recruiting
153 enrolled 15 charts
EndocrineHead & Neck

Differentiated Thyroid Cancer (DTC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡